



Demographics and socioeconomic

Total Population (in 1000) (2019)	74.14
Population <1 year of age (in 1000) (2019)	1.09
Population 1 year of age (in 1000)(2019)	1.09
Population <5 years of age (in 1000) (2019)	5.47
Women of childbearing age (2019)	36.18
Infant Mortality Rate (per 1000 live births) (2018)	13.80
Gross national income (US\$ per capita) current value (2018)	7,210.00
National Health Expenditure Public (2016)	3.41
National Health Expenditure Private (2016)	1.61

Immunization system highlights

- There is no comprehensive multi-year plan (MYP) for immunization.
- A standing national technical advisory group on immunization (NITAG) with formal written terms of reference exists. The group met 3 times in 2019.
- 96% of spending on routine immunization is financed using government funds.
- 100% of spending on vaccine purchases is financed using government funds.
- A national nominal electronic immunization registry implementation is in progress.


Immunization Schedule

DMA	Doses					
	1	2	3	4	5	6
BCG	B-1Y					
HepB_Pediatric	NB					
DTP-Hib						
DTP-Hib-HepB	2M	4M	6M			
DTP-Hib-IPV						
DTP-Hib-HepB-IPV						
DTP				18M	3Y	
IPV	2M					
OPV	4M	6M	18M	3Y	10-12Y	
MMR	12M	18M				
Pneumoco_conj						
Rotavirus						
Td					10-12Y and over	
Tdap						
HPV	Initial dose 11-12 year olds	6 M after 1st dose				

Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	2006
Hepatitis B	2006
HPV	
Influenza	
MMR1	1989
MMR2	2001
Pentavalent	2006
Pneumococcal Conjugate	
Rotavirus	
Tdap	
Tetavalent DPT-Hib or DPT-HepB	
Yellow Fever	

Vaccination Coverage



Surveillance Indicators - AFP (CARPHA)

2019

Number of AFP suspected cases	8
AFP rate per 100,000 population <15 years old	0.57
% of cases with 1 adequate sample	100
% of cases investigated within <48 hours	100
% sites reporting	83


Surveillance Indicators - MR (CARPHA)

2019


Number of suspected cases	371
% of cases with adequate investigation	86
% of cases with adequate blood samples	98
% of samples received in laboratory <=5 days	9
% of laboratory samples results <=4 days	83




Polio3 coverage and AFP rate per 100,000 children <15 years of age




DTP3 coverage and number of reported diphtheria and pertussis cases




Number of tetanus (no neonatal) and neonatal tetanus cases



Proportion of municipalities by coverage range with DTP3 in children <1 years of age



DTP1-DTP3 and DTP1-MMR1 Dropout Rate



Legend

NB/nb-newborn
M/m-month
Y/y-year
WCBA-women of childbearing age

● with stockout
● no stockout
● no data available

Vaccine Stockout

DMA	2013	2014	2015	2016	2017	2018	2019
AD Syringes							
BCG	●	●	●	●	●	●	●
Disposable Syringes	●	●		●	●	●	●
DTP	●	●	●	●	●	●	●
HepB	●	●	●	●	●	●	●
Hib	●	●	●	●	●	●	●
Influenza	●	●	●	●	●	●	●
IPV			●	●	●	●	●
Measles	●	●	●	●	●	●	●
Pneumo. Conjugate				●			
Polio	●	●	●	●	●	●	●
Reconst. Syringes		●		●			
Rotavirus				●			
Safety boxes	●	●	●	●	●	●	●
Tdap				●			
TT	●	●	●	●	●	●	●
Yellow Fever	●		●	●	●	●	●